Clinic
Deaconess Hospital, INC.
Deaconess Hospital, INC. was paid $77.38M by Medicaid between Jan 2018 and Dec 2024, across 298 billing codes. Its largest line is 99284, emergency room visit (serious) — 24% of everything it billed.
33Billing provider infoDEACONESS HOSPITAL, INC.
EVANSVILLE, IN 47710
EVANSVILLE, IN 47710
33aNPI1053361642assigned 05/12/2006
33bProvider typeMobile Mammography Clinic/Center
28Total paid$77.38M
24GClaims1,718,087
24DCodes billed298
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 229,459 | $4.57M | |
| 2019 | 215,228 | $7.21M | |
| 2020 | 229,781 | $10.03M | |
| 2021 | 325,539 | $15.70M | |
| 2022 | 314,501 | $15.54M | |
| 2023 | 233,823 | $14.26M | |
| 2024incomplete | 169,756 | $10.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 120,605 | 101,484 | $18.93M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 9.6% | 98,739 | 74,337 | $7.41M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.3% | 41,105 | 36,452 | $5.67M |
| 71045 | Radiologic examination, chest; single view | 5.5% | 35,901 | 29,740 | $4.24M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 8,712 | 7,186 | $3.04M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.9% | 44,545 | 36,834 | $3.01M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3.9% | 22,570 | 18,019 | $3.01M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.7% | 12,351 | 9,480 | $2.90M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.3% | 3,969 | 1,391 | $2.57M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.0% | 3,053 | 2,427 | $2.31M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.0% | 38,144 | 31,393 | $2.29M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.9% | 34,756 | 28,628 | $2.24M |
286 more codes
| 99218 | 1.6% | 4,935 | $1.26M | |
| 80050 | General health panel | 1.6% | 10,283 | $1.22M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.3% | 9,679 | $1.01M |
| 99213 | Doctor's office visit, returning patient (routine) | 1.0% | 9,989 | $805K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 7,545 | $781K |
| G0378 | Hospital observation service, per hour | <1% | 3,475 | $721K |
| 80053 | Comprehensive metabolic panel | <1% | 139,927 | $690K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 182,033 | $678K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,295 | $578K |
| 36415 | Collection of venous blood by venipuncture | <1% | 305,677 | $544K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,925 | $540K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 25,672 | $506K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 5,926 | $458K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,110 | $437K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 274 | $424K |
| 99217 | <1% | 943 | $351K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,618 | $342K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,318 | $292K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,255 | $286K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,249 | $276K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 466 | $269K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,913 | $257K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 9,525 | $247K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,525 | $247K |
| 97803 | <1% | 5,670 | $246K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,533 | $230K |
| 80061 | Lipid panel | <1% | 27,868 | $229K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 584 | $197K |
| 64493 | <1% | 436 | $196K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 148 | $184K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,823 | $176K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,748 | $171K |
| 99221 | <1% | 297 | $167K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,432 | $156K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,476 | $155K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 279 | $139K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,436 | $130K |
| 81001 | <1% | 64,422 | $125K | |
| 77336 | <1% | 928 | $112K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 21,234 | $109K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,961 | $105K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 893 | $105K |
| 84484 | <1% | 10,919 | $102K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 836 | $93K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 914 | $91K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,804 | $89K |
| 88342 | <1% | 2,016 | $83K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,474 | $82K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 184 | $79K |
| 83690 | <1% | 24,280 | $78K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,332 | $77K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,935 | $71K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,388 | $71K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,184 | $70K |
| 93798 | <1% | 585 | $69K | |
| 64494 | <1% | 473 | $67K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 5,881 | $66K |
| 85610 | <1% | 25,464 | $66K | |
| 80074 | <1% | 1,755 | $65K | |
| 97597 | <1% | 451 | $63K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,787 | $61K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 594 | $60K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 40 | $59K |
| 81513 | <1% | 122 | $55K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 22,929 | $55K |
| 29581 | <1% | 1,009 | $52K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,877 | $52K |
| 62323 | <1% | 79 | $47K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 6,051 | $47K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,459 | $45K |
| 84439 | <1% | 6,668 | $44K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 267 | $44K |
| 74018 | <1% | 479 | $39K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,140 | $39K |
| 81025 | <1% | 4,691 | $39K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,217 | $38K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,059 | $36K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 356 | $36K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 775 | $34K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 196 | $34K |
| 82947 | <1% | 4,184 | $31K | |
| 93880 | <1% | 398 | $31K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,162 | $31K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 58 | $29K |
| 86803 | <1% | 2,560 | $29K | |
| 82077 | <1% | 2,631 | $28K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,027 | $28K |
| 52000 | <1% | 70 | $28K | |
| 64490 | <1% | 124 | $28K | |
| 11043 | <1% | 27 | $26K | |
| 80320 | <1% | 924 | $25K | |
| 84703 | <1% | 4,568 | $25K | |
| 76801 | <1% | 151 | $25K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 684 | $25K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,537 | $24K |
| 87077 | <1% | 6,107 | $24K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 971 | $22K |
| 82803 | <1% | 1,568 | $21K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,619 | $21K |
| 84481 | <1% | 1,596 | $20K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 397 | $19K |
| 97802 | <1% | 206 | $19K | |
| 97161 | <1% | 844 | $18K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,569 | $18K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 928 | $17K |
| 77301 | <1% | 26 | $16K | |
| 43235 | <1% | 28 | $16K | |
| 64520 | <1% | 47 | $16K | |
| 87081 | <1% | 3,128 | $16K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 836 | $16K |
| 64495 | <1% | 277 | $15K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 124 | $15K |
| 85652 | <1% | 3,964 | $15K | |
| 76830 | Ultrasound, transvaginal | <1% | 70 | $15K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 71 | $15K |
| 86780 | <1% | 1,845 | $15K | |
| 87186 | <1% | 2,512 | $14K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 73 | $14K |
| C1769 | Guide wire | <1% | 221 | $14K |
| 90651 | <1% | 324 | $14K | |
| 64491 | <1% | 138 | $14K | |
| 86140 | <1% | 3,968 | $13K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 36 | $13K |
| 86762 | <1% | 1,178 | $13K | |
| 85730 | <1% | 1,134 | $12K | |
| 83605 | <1% | 1,750 | $12K | |
| 84145 | <1% | 773 | $12K | |
| 77300 | <1% | 89 | $12K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 74 | $12K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 13 | $11K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 244 | $11K |
| 83880 | <1% | 446 | $10K | |
| 83735 | <1% | 2,077 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 394 | $10K |
| 82607 | <1% | 849 | $10K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 52 | $9K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 70 | $9K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 17 | $8K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,315 | $8K |
| 81003 | <1% | 4,717 | $8K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 409 | $8K |
| 87340 | <1% | 1,138 | $7K | |
| 85379 | <1% | 1,052 | $7K | |
| 86850 | <1% | 1,626 | $7K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 40 | $7K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 985 | $7K |
| 87070 | <1% | 1,285 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 952 | $6K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 439 | $6K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 143 | $6K |
| 72131 | <1% | 31 | $6K | |
| 95816 | <1% | 12 | $6K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 94 | $6K |
| 82533 | <1% | 436 | $5K | |
| 83655 | <1% | 456 | $5K | |
| 90677 | <1% | 130 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 306 | $5K |
| 80076 | <1% | 1,420 | $5K | |
| 82746 | <1% | 373 | $4K | |
| 82950 | <1% | 1,139 | $4K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 293 | $4K |
| 82565 | <1% | 1,643 | $4K | |
| 0064U | <1% | 1,579 | $4K | |
| 82728 | <1% | 425 | $4K | |
| 84146 | <1% | 232 | $4K | |
| 82043 | <1% | 1,263 | $4K | |
| 87040 | <1% | 274 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 120 | $3K |
| 87905 | <1% | 356 | $3K | |
| 99188 | <1% | 28 | $3K | |
| 86003 | <1% | 62 | $3K | |
| 77338 | <1% | 26 | $3K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,139 | $3K |
| 87205 | <1% | 536 | $3K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 51 | $3K |
| 83540 | <1% | 656 | $3K | |
| 86901 | <1% | 1,174 | $3K | |
| 76937 | <1% | 98 | $3K | |
| 87481 | <1% | 86 | $3K | |
| 84403 | <1% | 112 | $3K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 12 | $3K |
| 36416 | <1% | 407 | $3K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 28 | $3K |
| 20553 | <1% | 15 | $3K | |
| 87641 | <1% | 178 | $3K | |
| 83550 | <1% | 347 | $2K | |
| 82550 | <1% | 452 | $2K | |
| 86900 | <1% | 957 | $2K | |
| 93320 | <1% | 464 | $2K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 332 | $2K |
| 84270 | <1% | 100 | $2K | |
| 90670 | <1% | 820 | $2K | |
| 99152 | <1% | 1,753 | $2K | |
| 82105 | <1% | 215 | $2K | |
| 64492 | <1% | 137 | $2K | |
| 87102 | <1% | 237 | $2K | |
| 95806 | <1% | 14 | $2K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 39 | $2K |
| 93325 | <1% | 430 | $2K | |
| 88300 | <1% | 90 | $2K | |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 33 | $2K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 408 | $1K |
| J1815 | Injection, insulin, per 5 units | <1% | 32 | $1K |
| 84702 | <1% | 254 | $1K | |
| 97116 | <1% | 281 | $1K | |
| 73630 | <1% | 40 | $1K | |
| 87563 | <1% | 33 | $1K | |
| 87206 | <1% | 237 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 28 | $1K |
| 94060 | <1% | 14 | $1K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 17 | $901.86 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 9,740 | $871.88 |
| 80055 | <1% | 31 | $835.78 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 83 | $823.72 |
| 82677 | <1% | 106 | $823.64 | |
| 72100 | <1% | 35 | $816.48 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 173 | $814.59 |
| 90686 | <1% | 3,459 | $798.15 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 54 | $787.70 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 25 | $774.48 |
| 87807 | <1% | 55 | $714.28 | |
| 0124A | <1% | 81 | $647.06 | |
| 91320 | <1% | 37 | $641.62 | |
| 90734 | <1% | 94 | $615.00 | |
| 86336 | <1% | 106 | $563.96 | |
| 82784 | <1% | 71 | $555.06 | |
| 81002 | <1% | 254 | $521.94 | |
| 72040 | <1% | 13 | $515.16 | |
| 85027 | <1% | 84 | $506.40 | |
| 82657 | <1% | 28 | $482.70 | |
| 90656 | <1% | 105 | $424.05 | |
| 86039 | <1% | 57 | $420.98 | |
| 87210 | <1% | 111 | $414.64 | |
| 0004A | <1% | 42 | $412.67 | |
| 84156 | <1% | 210 | $409.57 | |
| 82570 | <1% | 138 | $398.66 | |
| 86364 | <1% | 42 | $392.02 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 115 | $390.43 |
| 85018 | <1% | 160 | $373.56 | |
| 90715 | <1% | 411 | $357.52 | |
| 73610 | <1% | 13 | $341.45 | |
| 84207 | <1% | 14 | $289.43 | |
| 80069 | <1% | 98 | $276.44 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 21 | $264.60 |
| 87420 | <1% | 20 | $235.05 | |
| 90480 | <1% | 37 | $232.22 | |
| 88142 | <1% | 17 | $210.70 | |
| 84479 | <1% | 69 | $195.16 | |
| 80164 | <1% | 31 | $194.57 | |
| 84436 | <1% | 55 | $179.66 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 20 | $174.79 |
| 84144 | <1% | 13 | $168.32 | |
| 82375 | <1% | 35 | $165.21 | |
| 88112 | <1% | 30 | $151.59 | |
| 83516 | <1% | 12 | $138.36 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 2,123 | $111.84 |
| 90698 | <1% | 464 | $97.86 | |
| 84100 | <1% | 30 | $94.08 | |
| 84134 | <1% | 27 | $69.47 | |
| 84550 | <1% | 15 | $53.42 | |
| 82962 | <1% | 21 | $47.54 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,034 | $47.44 |
| 83615 | <1% | 16 | $45.52 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 19 | $38.24 |
| 0001A | <1% | 37 | $37.21 | |
| 84460 | <1% | 38 | $31.86 | |
| 94727 | 0% | 14 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 3,488 | $0.00 |
| 90473 | 0% | 277 | $0.00 | |
| 91300 | 0% | 50 | $0.00 | |
| 91312 | 0% | 81 | $0.00 | |
| 90633 | 0% | 132 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 13 | $0.00 |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 0% | 29 | $0.00 |
| 0002A | 0% | 37 | $0.00 | |
| 94729 | 0% | 16 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 224 | $0.00 |
| 90744 | 0% | 136 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 151 | $0.00 |
| 90680 | 0% | 302 | $0.00 | |
| 81511 | 0% | 93 | $0.00 | |
| 90619 | 0% | 29 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 16 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 44 | $0.00 |
| 91305 | 0% | 21 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 47 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCOY, SHAWN (PRESIDENT AND CEO)
| Provider | Location | Paid |
|---|---|---|
| Eclipse Medical, LLC | North Little Rock, AR | $1.12M |
| Deaconess Hospital, INC. | Boonville, IN | $175K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.